Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases Research, 88397 Biberach an der Riss, Germany.
Neurobiol Dis. 2013 Jun;54:280-8. doi: 10.1016/j.nbd.2012.12.019. Epub 2013 Jan 11.
Recent studies indicate that the Parkinson's disease-linked leucine-rich repeat kinase 2 (LRRK2) modulates cytoskeletal functions by regulating actin and tubulin dynamics, thereby affecting neurite outgrowth. By interactome analysis we demonstrate that the binding of LRRK2 to tubulins is significantly enhanced by pharmacological LRRK2 inhibition in cells. Co-incubation of LRRK2 with microtubules increased the LRRK2 GTPase activity in a cell-free assay. Destabilization of microtubules causes a rapid decrease in cellular LRRK2(S935) phosphorylation indicating a decreased LRRK2 kinase activity. Moreover, both human LRRK2(G2019S) fibroblasts and mouse LRRK2(R1441G) fibroblasts exhibit alterations in cell migration in culture. Treatment of mouse fibroblasts with the selective LRRK2 inhibitor LRRK2-IN1 reduces cell motility. These findings suggest that LRRK2 and microtubules mutually interact both in non-neuronal cells and in neurons, which might contribute to our understanding of its pathogenic effects in Parkinson's disease.
最近的研究表明,帕金森病相关的亮氨酸丰富重复激酶 2(LRRK2)通过调节肌动蛋白和微管动力学来调节细胞骨架功能,从而影响神经突的生长。通过互作分析,我们证明细胞中药理学 LRRK2 抑制可显著增强 LRRK2 与微管的结合。在无细胞测定中,LRRK2 与微管共孵育可增加 LRRK2 GTPase 活性。微管的不稳定导致细胞内 LRRK2(S935)磷酸化迅速减少,表明 LRRK2 激酶活性降低。此外,人 LRRK2(G2019S)成纤维细胞和小鼠 LRRK2(R1441G)成纤维细胞在培养中均表现出细胞迁移的改变。用选择性 LRRK2 抑制剂 LRRK2-IN1 处理小鼠成纤维细胞可降低细胞迁移率。这些发现表明,LRRK2 和微管在非神经元细胞和神经元中相互作用,这可能有助于我们理解其在帕金森病中的致病作用。